Celecoxib in Parkinson Disease as Adjuvant Therapy

Condition(s) studied

Investigational drug(s) / intervention(s)

Levodopa Carbidopa: Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

Celecoxib 200mg: Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)

Study summary

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Eligibility

Primary outcome measure(s)

• change in the Unified Parkinson's Disease Rating Scale — 6 months
  \- Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

Trial sites (1)

More Tanta University trials in Egypt

Other trials for the same condition